Sherene Loi - Concepedia

Author

Sherene Loi

Also Known As

Axel Le Cesne, C. Denkert, El-Abed, S, Geoff Lindeman, Gray, Daniel H. D., Linda R. Mileshkin, Liz Lobb, Loi, Sherene, M. Piccart, Renea Taylor

1.2K

Publications

77.2K

Citations

125

H-Index

110

Concepts

All Affiliations

Peter MacCallum Cancer Centre The University of Melbourne Institut Jules Bordet Dana-Farber Cancer Institute European Institute of Oncology

About

Sherene Loi is an author at Peter MacCallum Cancer Centre specializing in medicine, oncology, and breast cancer.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	58	145	27.9K
2	Health Sciences	19	28	8.3K
3	Biostatistics	9	9	2.4K
4	Public Health	6	6	344
5	Engineering	5	5	2.7K

Sherene Loi

310

Publications

64.5K

Citations

108

H-Index

Page 1

	Year	Citations
Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer Peter Schmid, Sylvia Adams, Hope S. Rugo, New England Journal of Medicine	2018	4.2K
The evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer: recommendations by an International TILs Working Group 2014 Roberto Salgado, Carsten Denkert, Sandra Demaria, Annals of Oncology Lymphoid NeoplasiaBreast OncologyCancer ImmunosurveillanceMedicineImmunology	2014	3K
Gene Expression Profiling in Breast Cancer: Understanding the Molecular Basis of Histologic Grade To Improve Prognosis Christos Sotiriou, Pratyaksha Wirapati, Sherene Loi, JNCI Journal of the National Cancer Institute Breast OncologyEngineeringPathologyHistologic GradeCancer Biology	2006	2.1K
Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial Massimo Cristofanilli, Nicholas C. Turner, Igor Bondarenko, The Lancet Oncology Breast OncologyHealth SciencesMedicinePharmacologyClinical Trials	2016	1.8K
Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a randomised, placebo-controlled, double-blind, phase 3 clinical trial Javier Cortés, David W. Cescon, Hope S. Rugo, The Lancet Chemotherapy Versus PlaceboBreast OncologyOncologyClinical TrialsBreast Cancer	2020	1.7K
Prognostic and Predictive Value of Tumor-Infiltrating Lymphocytes in a Phase III Randomized Adjuvant Breast Cancer Trial in Node-Positive Breast Cancer Comparing the Addition of Docetaxel to Doxorubicin With Doxorubicin-Based Chemotherapy: BIG 02-98 Sherene Loi, Nicolas Sirtaine, Fanny Piette, Journal of Clinical Oncology	2013	1.6K
Palbociclib in Hormone-Receptor–Positive Advanced Breast Cancer Nicholas C. Turner, Jungsil Ro, Fabrice André, New England Journal of Medicine	2015	1.5K
Tucatinib, Trastuzumab, and Capecitabine for HER2-Positive Metastatic Breast Cancer Rashmi K. Murthy, Sherene Loi, Alicia Okines, New England Journal of Medicine	2019	1.3K
ESMO Clinical Practice Guideline for the diagnosis, staging and treatment of patients with metastatic breast cancer Alessandra Gennari, Fabrice André, Carlos H. Barrios, Annals of Oncology Surgical OncologyMetastatic Breast CancerBreast OncologyMedicineCancer Management	2021	1.3K
Tumor infiltrating lymphocytes are prognostic in triple negative breast cancer and predictive for trastuzumab benefit in early breast cancer: results from the FinHER trial Sherene Loi, Stefan Michiels, Roberto Salgado, Annals of Oncology Breast OncologyCancer ImmunosurveillanceMedicineImmunologyPathology	2014	1.3K

Page 1